论文部分内容阅读
为了解重组组织型纤溶酶原激活剂(rt-PA)治疗急性大片肺栓塞时静脉给药是否与肺动脉给药同样有效以及消除大部分造影可见的栓塞,使患者血液动力学恢复正常所需rt-PA的剂量和副作用,欧洲八个医学中心联合对34例21～75岁的急性大片肺栓塞患者进行了研究。造影所见肺血管阻塞均>48%,按Miller方法估测栓塞程度,得分均>15(Br Heart J 1971,2:168)。随机分为肺动脉给药组(19例),外周静脉给药组(15例)。由发病到治疗间隔时间平均分别
In order to understand whether intravenous administration of recombinant tissue plasminogen activator (rt-PA) is as effective as pulmonary arterial administration in the treatment of acute large pulmonary embolism and to eliminate the majority of angiographic emboli, the patient is required to return to normal hemodynamics rt-PA dose and side effects, eight European centers of medicine jointly 34 cases of 21 to 75 years old patients with acute large pulmonary embolism were studied. Angiography findings of pulmonary vascular occlusion were> 48%, according to the Miller method to assess embolism, scores were> 15 (Br Heart J 1971, 2: 168). Randomly divided into pulmonary artery administration group (19 cases), peripheral vein administration group (15 cases). From onset to treatment interval averaged respectively